Ninepoint Partners’s Boston Scientific BSX Stock Holding History

Ninepoint Partners’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-30,000	Closed	-$1.22M	–	78
2019 Q3	$1.22M	Sell	30,000 -10,000	-25%	-$424K	0.47%	28
2019 Q2	$1.72M	Buy	+40,000	New	+$1.54M	0.32%	33
2018 Q4	–	Sell	-100,000	Closed	-$3.85M	–	71
2018 Q3	$3.85M	Buy	+100,000	New	+$3.49M	0.67%	32

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ninepoint Partners's BSX Position: Q3 2025 in Review

Ninepoint Partners sold out of Boston Scientific (BSX) in Q3 2025, closing a stake of 7,502 shares — an estimated $806K sold.

Ninepoint Partners first reported a position in BSX in Q3 2018 and held it in 10 quarters. The position peaked at $4.79M in Q3 2018. 1,708 funds tracked by Wall St. Rank hold BSX as of Q3 2025.

Ninepoint Partners reported no remaining Boston Scientific position as of Q3 2025 after selling out during the quarter.
Ninepoint Partners sold 7,502 Boston Scientific shares in Q3 2025, an estimated $806K.
Ninepoint Partners first reported a position in Boston Scientific in Q3 2018 and held it in 10 quarters.
Ninepoint Partners's Boston Scientific position peaked at $4.79M in Q3 2018.
1,708 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2025.

Based on Ninepoint Partners's 13F filing for Q3 2025, filed 12 Nov 2025.